HLVX Key Statistics, Chart & Performance
The current stock price of HLVX is 2.09 USD. In the past month the price increased by 1.46%. In the past year, price increased by 16.11%.
HLVX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to HLVX. When comparing the yearly performance of all stocks, HLVX is one of the better performing stocks in the market, outperforming 74.76% of all stocks.
HLVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HLVX. While HLVX has a great health rating, there are worries on its profitability.
HLVX Financial Highlights
Over the last trailing twelve months HLVX reported a non-GAAP Earnings per Share(EPS) of -1.43. The EPS increased by 57.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.65% | ||
| ROE | -48.1% | ||
| Debt/Equity | 0 |
HLVX Forecast & Estimates
6 analysts have analysed HLVX and the average price target is 2.04 USD. This implies a price decrease of -2.39% is expected in the next year compared to the current price of 2.09.
HLVX Ownership
HLVX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HLVX
Company Profile
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Company Info
HILLEVAX INC
321 Harrison Ave, Suite 500
Boston MASSACHUSETTS US
Employees: 14
Phone: 16172135054
HILLEVAX INC / HLVX FAQ
Can you describe the business of HILLEVAX INC?
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Can you provide the latest stock price for HILLEVAX INC?
The current stock price of HLVX is 2.09 USD. The price decreased by -0.48% in the last trading session.
Does HLVX stock pay dividends?
HLVX does not pay a dividend.
How is the ChartMill rating for HILLEVAX INC?
HLVX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does HILLEVAX INC have?
HILLEVAX INC (HLVX) currently has 14 employees.
What is the market capitalization of HLVX stock?
HILLEVAX INC (HLVX) has a market capitalization of 104.79M USD. This makes HLVX a Micro Cap stock.
Can you provide the ownership details for HLVX stock?
You can find the ownership structure of HILLEVAX INC (HLVX) on the Ownership tab.